Using the Lower Limit of Normal Instead of the Conventional Cutoff Values to Define Predictors of Pulmonary Function Impairment in Subjects With Chronic Heart Failure
Restricted accessResearch articleFirst published online February, 2016
Using the Lower Limit of Normal Instead of the Conventional Cutoff Values to Define Predictors of Pulmonary Function Impairment in Subjects With Chronic Heart Failure
Using the newer lower limit of normal criterion instead of the conventional cutoff values to define pulmonary function abnormalities may result in different predictors of pulmonary function impairment in patients with heart failure. Therefore, we assessed predictors of pulmonary function impairment in subjects with chronic heart failure according to the lower limit of normal in comparison with conventional cutoff values.
METHODS:
In this prospective cross-sectional study, 164 chronic heart failure subjects (age 68 ± 10 y, 78% men, 88% New York Heart Association class I-II) with left ventricular ejection fraction <40% underwent pulmonary function tests. Predictors of pulmonary function impairment were assessed using the lower limit of normal and conventional cutoff values (ie, 80% predicted value and the fixed ratio of FEV1/FVC <0.7).
RESULTS:
The lower limit of normal criterion identified an extra independent predictor of diffusion impairment compared with the 80% predicted value; in addition to body mass index, pack-years, and alveolar volume, female sex also turned out to be an independent predictor. A smoking history of ≥10 pack-years was a significant predictor of diffusion impairment and airway obstruction using the lower limit of normal criterion but not using the conventional cutoff values. However, lowering the cutoff points of conventional criteria to match the more stringent lower limit of normal and thus avoid overdiagnosis of diffusion impairment and airway obstruction in the elderly produced similar results as the lower limit of normal.
CONCLUSIONS:
The lower limit of normal identifies more predictors of diffusion impairment and airway obstruction compared with conventional cutoff values in subjects with chronic heart failure with left ventricular systolic dysfunction. However, lowering the conventional cutoff points yielded similar results as the lower limit of normal. (ClinicalTrials.gov registration NCT01429376.)
GehlbachBK, GeppertE. The pulmonary manifestations of left heart failure. Chest, 2004; 125(2):669–682.
5.
ChuaTP, CoatsAJ. The lungs in chronic heart failure. Eur Heart J, 1995; 16(7):882–887.
6.
FaggianoP. Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol, 1994; 44(1):1–8.
7.
SnashallPD, ChungKF. Airway obstruction and bronchial hyperresponsiveness in left ventricular failure and mitral stenosis. Am Rev Respir Dis, 1991; 144(4):945–956.
8.
ManciniDM. Pulmonary factors limiting exercise capacity in patients with heart failure. Prog Cardiovasc Dis, 1995; 37(6):347–370.
9.
PuriS, BakerBL, DutkaDP, OakleyCM, HughesJM, ClelandJG. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation, 1995; 91(11):2769–2774.
10.
KraemerMD, KuboSH, RectorTS, BrunsvoldN, BankAJ. Pulmonary and peripheral vascular factors are important determinants of peak exercise oxygen uptake in patients with heart failure. J Am Coll Cardiol, 1993; 21(3):641–648.
11.
DimopoulouI, DaganouM, TsintzasOK, TzelepisGE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med, 1998; 92(12):1321–1325.
12.
TzaniP, PiepoliMF, LongoF, AielloM, SerraW, MaurizioAR, et al. Resting lung function in the assessment of the exercise capacity in patients with chronic heart failure. Am J Med Sci, 2010; 339(3):210–215.
13.
JohnsonBD, BeckKC, OlsonLJ, O'MalleyKA, AllisonTG, SquiresRW, GauGT. Pulmonary function in patients with reduced left ventricular function: influence of smoking and cardiac surgery. Chest, 2001; 120(6):1869–1876.
14.
WrightRS, LevineMS, BellamyPE, SimmonsMS, BatraP, StevensonLW, et al. Ventilatory and diffusion abnormalities in potential heart transplant recipients. Chest, 1990; 98(4):816–820.
15.
SobolBJ, SobolPG. Per cent of predicted as the limit of normal in pulmonary function testing: a statistically valid approach. Thorax, 1979; 34(1):1–3.
16.
PellegrinoR, ViegiG, BrusascoV, CrapoRO, BurgosF, CasaburiR, et al. Interpretative strategies for lung function tests. Eur Respir J, 2005; 26(5):948–968.
17.
MinasianAG, van den ElshoutFJ, DekhuijzenPN, VosPJ, WillemsFF, van den BerghPJ, HeijdraYF. Pulmonary function impairment in patients with chronic heart failure: lower limit of normal versus conventional cutoff values. Heart Lung, 2014; 43(4):311–316.
18.
MillerMR, QuanjerPH, SwanneyMP, RuppelG, EnrightPL. Interpreting lung function data using 80 percent of predicted and fixed thresholds misclassifies over 20% of patients. Chest, 2011; 139(1):52–59.
19.
DicksteinK, Cohen-SolalA, FilippatosG, McMurrayJJ, PonikowskiP, Poole-WilsonPA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008; 29(19):2388–2442.
20.
O'HanlonR, O'SheaP, LedwidgeM, O'LoughlinC, LangeS, ConlonC, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail, 2007; 13(1):50–55.
21.
QuanjerPH, TammelingGJ, CotesJE, PedersenOF, PeslinR, YernaultJC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl, 1993; 16:5–40.
22.
RabeKF, HurdS, AnzuetoA, BarnesPJ, BuistSA, CalverleyP, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007; 176(6):532–555.
23.
Bourjeily-HabrG, RochesterCL, PalermoF, SnyderP, MohseninV. Randomised controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease. Thorax, 2002; 57(12):1045–1049.
24.
TownsendMC. Conflicting definitions of airways obstruction: Drawing the line between normal and abnormal. Chest, 2007; 131(2):335–336.
25.
de MarcoR, AccordiniS, MarconA, CerveriI, AntoJM, GislasonT, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med, 2011; 183(7):891–897.
26.
ManninoDM, Diaz-GuzmanE. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest, 2012; 141(1):73–80.
27.
GuazziM. Alveolar-capillary membrane dysfunction in chronic heart failure: pathophysiology and therapeutic implications. Clin Sci, 2000; 98(6):633–641.
28.
BussièresLM, PflugfelderPW, AhmadD, TaylorAW, KostukWJ. Evolution of resting lung function in the first year after cardiac transplantation. Eur Respir J, 1995; 8(6):959–962.
29.
GuazziM, MelziG, AgostoniP. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1997; 80(12):1572–1576.
30.
GuazziM, MarenziG, AlimentoM, ContiniM, AgostoniP. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation, 1997; 95(7):1930–1936.
31.
GuazziM, AgostoniP, GuazziMD. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. J Am Coll Cardiol, 2001; 37(2):398–406.
32.
HarmsCA, RosenkranzS. Sex differences in pulmonary function during exercise. Med Sci Sports Exerc, 2008; 40(4):664–668.
33.
SalomeCM, KingGG, BerendN. Physiology of obesity and effects on lung function. J Appl Physiol, 2010; 108(1):206–211.
34.
OlsonTP, BeckKC, JohnsonBD. Pulmonary function changes associated with cardiomegaly in chronic heart failure. J Card Fail, 2007; 13(2):100–107.
35.
AgostoniP, CattadoriG, GuazziM, PalermoP, BussottiM, MarenziG. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. Am Heart J, 2000; 140(5):e24.
36.
TanabeT, KanohS, MoskowitzWB, RubinBK. Cardiac asthma: TGF-β from the failing heart leads to squamous metaplasia in human airway cells and in the murine lung. Chest, 2012; 142(5):1274–1283.
37.
BrennerS, GüderG, BerlinerD, DeubnerN, FröhlichK, ErtlG, et al. Airway obstruction in systolic heart failure: COPD or congestion?. Int J Cardiol, 2013; 168(3):1910–1916.
38.
RossiA, AisanovZ, AvdeevS, Di MariaG, DonnerCF, IzquierdoJL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med, 2015; 109(7):785–802.
39.
GuazziM, PontoneG, BrambillaR, AgostoniP, RèinaG. Alveolar–capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J, 2002; 23(6):467–476.
40.
IversenKK, KjaergaardJ, AkkanD, KoberL, Torp-PedersenC, HassagerC, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail, 2010; 12(7):685–691.
O'KellyN, RobertsonW, SmithJ, DexterJ, Carroll-HawkinsC, GhoshS. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol, 2012; 4(3):66–71.
43.
LightRW, GeorgeRB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med, 1983; 143(3):429–433.
44.
FaggianoP, LombardiC, SorgatoA, GhizzoniG, SpediniC, RusconiC. Pulmonary function tests in patients with congestive heart failure: effects of medical therapy. Cardiology, 1993; 83(1):30–35.
45.
NisetG, NinaneV, AntoineM, YernaultJC. Respiratory dysfunction in congestive heart failure: correction after heart transplantation. Eur Respir J, 1993; 6(8):1197–1201.
46.
PetersenCL, KjaerA. Impact of medical treatment on lung diffusion capacity in elderly patients with heart failure. Baseline characteristics and 1-year follow up after medical treatment. Int J Cardiol, 2005; 98(3):453–457.
47.
MinasianAG, van den ElshoutFJ, DekhuijzenPN, VosPJ, WillemsFF, van den BerghPJ, HeijdraYF. Bronchodilator responsiveness in patients with chronic heart failure. Heart Lung, 2013; 42(3):208–214.
48.
KindmanLA, VagelosRH, WillsonK, PrikazkyL, FowlerM. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide. Am J Cardiol, 1994; 73(4):258–262.
49.
UrenNG, DaviesSW, JordanSL, LipkinDP. Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure. Eur Heart J, 1993; 14(6):744–750.
50.
KhanKA, JalalS, JanVM, LoneGM, JanR, AlaiMS, et al. Pulmonary function profile in chronic congestive heart failure and the effect of ipratropium bromide. Indian Heart J, 2000; 52(3):297–300.
51.
WitteKK, MoriceA, ClelandJG, ClarkAL. The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry. J Card Fail, 2004; 10(2):149–154.
52.
RollaG, BuccaC, BrussinoL, GalloW, MalaraD. Bronchodilating effect of ipratropium bromide in heart failure. Eur Respir J, 1993; 6(10):1492–1495.
KurzawaR, BaronT, GrodzickiT. Pulmonary function test abnormalities in the elderly with systolic heart failure. Kardiol Pol, 65(8):875–880, 2007; discussion 881-872.
